Ras-related C3 botulinum toxin substrate 1 (RAC1) overexpression has been implicated in multiple cancer cell phenotypes associated with tumor progression, metastasis, therapeutic resistance, and an overall worse prognosis for patients across a variety of solid tumors [1,2,3]. Here, RAC1 is linked to cancer.